CA2990686A1 - Methods of preventing toxicity of platinum drugs comprising administering an oct monitor - Google Patents

Methods of preventing toxicity of platinum drugs comprising administering an oct monitor Download PDF

Info

Publication number
CA2990686A1
CA2990686A1 CA2990686A CA2990686A CA2990686A1 CA 2990686 A1 CA2990686 A1 CA 2990686A1 CA 2990686 A CA2990686 A CA 2990686A CA 2990686 A CA2990686 A CA 2990686A CA 2990686 A1 CA2990686 A1 CA 2990686A1
Authority
CA
Canada
Prior art keywords
oct2
subject
platinum drug
cancer
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2990686A
Other languages
English (en)
French (fr)
Inventor
Yong Huang
Dominique P. Bridon
Xuexiang ZHANG
Chien-Ming Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xomics Biopharma Inc
Original Assignee
Amari Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amari Biopharma Inc filed Critical Amari Biopharma Inc
Publication of CA2990686A1 publication Critical patent/CA2990686A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2990686A 2015-07-16 2016-07-15 Methods of preventing toxicity of platinum drugs comprising administering an oct monitor Pending CA2990686A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193529P 2015-07-16 2015-07-16
US62/193,529 2015-07-16
PCT/US2016/042673 WO2017011816A1 (en) 2015-07-16 2016-07-15 Methods of preventing toxicity of platinum drugs

Publications (1)

Publication Number Publication Date
CA2990686A1 true CA2990686A1 (en) 2017-01-19

Family

ID=57757682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2990686A Pending CA2990686A1 (en) 2015-07-16 2016-07-15 Methods of preventing toxicity of platinum drugs comprising administering an oct monitor

Country Status (6)

Country Link
US (2) US11197862B2 (https=)
EP (2) EP3777851B1 (https=)
JP (2) JP6851639B2 (https=)
CN (1) CN108024986A (https=)
CA (1) CA2990686A1 (https=)
WO (1) WO2017011816A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990686A1 (en) * 2015-07-16 2017-01-19 Amari Biopharma, Inc. Methods of preventing toxicity of platinum drugs comprising administering an oct monitor
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
WO2021034627A1 (en) * 2019-08-16 2021-02-25 Purdue Research Foundation Small molecule stimulators of the core particle of the proteasome
CN111067894A (zh) * 2020-01-14 2020-04-28 广东药科大学 咪康唑在制备抗肺鳞癌药物和顺铂增敏剂中的应用
CN111110675A (zh) * 2020-02-25 2020-05-08 浙江大学 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
CN113527333B (zh) * 2020-04-13 2022-08-05 南开大学 具有生物活性的度鲁特韦衍生物及其制备方法和应用
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032172A2 (en) * 2007-08-31 2009-03-12 Massachusetts Institute Of Technology Platinum compositions as treatment for oct-related cancers
ES2665042T3 (es) 2008-02-18 2018-04-24 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos que se unen a ligandos del receptor sigma para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
EP2090311A1 (en) * 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
EP2854829A1 (en) * 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
CA2891855A1 (en) 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
CA2990686A1 (en) * 2015-07-16 2017-01-19 Amari Biopharma, Inc. Methods of preventing toxicity of platinum drugs comprising administering an oct monitor

Also Published As

Publication number Publication date
US11197862B2 (en) 2021-12-14
JP2021080296A (ja) 2021-05-27
JP7117797B2 (ja) 2022-08-15
EP3777851B1 (en) 2022-12-28
WO2017011816A1 (en) 2017-01-19
US20220202823A1 (en) 2022-06-30
US20180207169A1 (en) 2018-07-26
JP2018521133A (ja) 2018-08-02
JP6851639B2 (ja) 2021-03-31
EP3322414A1 (en) 2018-05-23
EP3322414B1 (en) 2020-09-30
CN108024986A (zh) 2018-05-11
EP3322414A4 (en) 2019-02-06
EP3777851A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
CA2990686A1 (en) Methods of preventing toxicity of platinum drugs comprising administering an oct monitor
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
ES2992827T3 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
Qi et al. Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth
US20140024653A1 (en) Compositions and methods for treating cancer using pi3k inhibitor and mek inhibitor
US20170071903A1 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
EP4537832A1 (en) Method for treating cancer patient with akr1c3 enzyme-activated prodrug
US20250186468A1 (en) Method for treating patient with brca-mutated cancer
Chen et al. Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia
US20160250220A1 (en) Treatment for pancreatic cancer
US20210259995A1 (en) Methods for inhibiting growth of acsl4-overexpressing tumors
US20180169123A1 (en) Combination therapy with a flavagline and 2-deoxyglucose
Pisano et al. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine
JP7361779B2 (ja) がんに治療的処置をするためのｃ－１９ステロイドの組み合わせ
US20230158042A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
US20230149358A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
JP2018501304A (ja) シナラ・スコリムスの滴定抽出物及びそれらの使用
Cham et al. Discovery of Ring-Annulated Analogues of Cannabidiol as Potential Anticancer Agents: Synthesis and Biological Evaluation
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
HK40047406A (en) Selective oct2 inhibitors for use in preventing toxicity of platinum drugs
HK1254122A1 (en) Methods of preventing toxicity of platinum drugs
AU2018244806A1 (en) An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer
WO2016003886A1 (en) 4-aminoquinoline compositions and methods for using same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210713